EADV 2020: Lilly and Incyte Showcase New Data for Baricitinib for the Treatment of Moderate to Severe Atopic Dermatitis

Latest baricitinib data highlight long-term efficacy and safety results from BREEZE-AD3 trial.

Baricitinib was recently approved by the European Commission, representing the first global approval for the medicine in atopic dermatitis.